Recruitment unclearEUCTR 2017-001169-26
An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as...
This historical record does not confirm current site availability.
Historical research recordPoland + United KingdomSchizophrenia
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Poland · United Kingdom
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- 348
- Sponsor
- SyneuRx International (Taiwan) Corp
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United Kingdom, Poland
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2017-001169-26
- Official title
Show the full official title
An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as...
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Poland · United Kingdom
Registry details
Historical country statuses
- United Kingdom — GB - no longer in EU/EEA
- Poland — Completed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is SyneuRx International (Taiwan) Corp.
